DANIEL K SPIEGELMAN Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for DANIEL K SPIEGELMAN.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of DANIEL K SPIEGELMAN. DANIEL K SPIEGELMAN is Senior Vice President and CFO in CV THERAPEUTICS INC ($CVTX) and Director in MYRIAD GENETICS INC ($MYGN) and EVP, Chief Financial Officer in BIOMARIN PHARMACEUTICAL INC ($BMRN) and Director in Oncothyreon Inc. ($ONTY) and Director in Relypsa Inc ($RLYP).
Latest Insider Trading Transactions of DANIEL K SPIEGELMAN
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, BMRN, CASC, CVTX, MYGN, RLYP
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 28 2021 | MYGN | MYRIAD GENETICS IN ... | SPIEGELMAN DANIEL K | Director | Sell | D | 0.00 | 15,889 | 0 | 20,562 | 36.5 K to 20.6 K (-43.59 %) |
Dec 07 2020 | MYGN | MYRIAD GENETICS IN ... | SPIEGELMAN DANIEL K | Director | Grant | A | 0.00 | 15,889 | 0 | 36,451 | 20.6 K to 36.5 K (+77.27 %) |
May 28 2020 | MYGN | MYRIAD GENETICS IN ... | SPIEGELMAN DANIEL K | Director | Grant | A | 0.00 | 20,562 | 0 | 20,562 | 0 to 20.6 K |
Jun 07 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 68.78 | 176 | 12,106 | 47,686 | 47.5 K to 47.7 K (+0.37 %) |
Apr 03 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 89.00 | 13,473 | 1,199,097 | 47,510 | 61 K to 47.5 K (-22.09 %) |
Mar 29 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 90.00 | 100 | 9,000 | 60,983 | 61.1 K to 61 K (-0.16 %) |
Mar 26 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 88.05 | 3,598 | 316,804 | 61,083 | 64.7 K to 61.1 K (-5.56 %) |
Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Option Exercise | A | 94.53 | 23,450 | 2,216,729 | 23,450 | |
Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 9,370 | 0 | 64,681 | 55.3 K to 64.7 K (+16.94 %) |
Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 94.53 | 7,227 | 683,168 | 55,311 | 62.5 K to 55.3 K (-11.56 %) |
Mar 05 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 94.76 | 912 | 86,421 | 62,538 | 63.5 K to 62.5 K (-1.44 %) |
Mar 05 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 12,205 | 0 | 63,450 | 51.2 K to 63.5 K (+23.82 %) |
Dec 20 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 68.78 | 175 | 12,037 | 51,245 | 51.1 K to 51.2 K (+0.34 %) |
Jun 26 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 99.01 | 472 | 46,733 | 51,070 | 51.5 K to 51.1 K (-0.92 %) |
Jun 26 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 99.00 | 9,528 | 943,272 | 51,542 | 61.1 K to 51.5 K (-15.60 %) |
Jun 26 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 99.01 | 472 | 46,733 | 51,070 | 51.5 K to 51.1 K (-0.92 %) |
Jun 26 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 99.00 | 9,528 | 943,272 | 51,542 | 61.1 K to 51.5 K (-15.60 %) |
Jun 06 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 92.07 | 1,711 | 157,532 | 61,070 | 62.8 K to 61.1 K (-2.73 %) |
Jun 06 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 68.78 | 167 | 11,487 | 62,781 | 62.6 K to 62.8 K (+0.27 %) |
Apr 25 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 82.15 | 11,059 | 908,497 | 62,543 | 73.6 K to 62.5 K (-15.03 %) |
Apr 25 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 82.15 | 11,059 | 908,497 | 62,543 | 73.6 K to 62.5 K (-15.03 %) |
Mar 26 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 81.36 | 3,583 | 291,513 | 73,602 | 77.2 K to 73.6 K (-4.64 %) |
Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Option Exercise | A | 83.57 | 39,900 | 3,334,443 | 39,900 | |
Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 12,480 | 0 | 77,185 | 64.7 K to 77.2 K (+19.29 %) |
Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 83.57 | 3,815 | 318,820 | 64,705 | 68.5 K to 64.7 K (-5.57 %) |
Mar 13 2018 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Option Exercise | D | 0.00 | 13,927 | 0 | 0 | |
Mar 13 2018 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Sell | U | 0.00 | 21,006 | 0 | 0 | 21 K to 0 (-100.00 %) |
Mar 06 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 79.86 | 1,609 | 128,495 | 68,520 | 70.1 K to 68.5 K (-2.29 %) |
Feb 28 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 12,529 | 0 | 70,129 | 57.6 K to 70.1 K (+21.75 %) |
Sep 26 2017 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Option Exercise | M | 0.00 | 2,375 | 0 | 0 | |
Sep 26 2017 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Payment of Exercise | F | 3.94 | 594 | 2,340 | 21,006 | 21.6 K to 21 K (-2.75 %) |
Sep 26 2017 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Buy | M | 0.00 | 2,375 | 0 | 21,600 | 19.2 K to 21.6 K (+12.35 %) |
Jun 27 2017 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Option Exercise | M | 0.00 | 9,058 | 0 | 0 | |
Jun 27 2017 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Payment of Exercise | F | 3.78 | 2,265 | 8,562 | 19,225 | 21.5 K to 19.2 K (-10.54 %) |
Jun 27 2017 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Buy | M | 0.00 | 9,058 | 0 | 21,490 | 12.4 K to 21.5 K (+72.86 %) |
Jun 13 2017 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Option Exercise | M | 0.00 | 2,148 | 0 | 0 | |
Jun 13 2017 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Option Exercise | A | 0.00 | 13,927 | 0 | 13,927 | |
Jun 13 2017 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Payment of Exercise | F | 3.34 | 537 | 1,794 | 12,432 | 13 K to 12.4 K (-4.14 %) |
Jun 13 2017 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Buy | M | 0.00 | 2,148 | 0 | 12,969 | 10.8 K to 13 K (+19.85 %) |
Jun 06 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 90.72 | 1,801 | 163,387 | 23,303 | 25.1 K to 23.3 K (-7.17 %) |
May 17 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 91.50 | 1,722 | 157,563 | 25,104 | 26.8 K to 25.1 K (-6.42 %) |
May 17 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 70.30 | 155 | 10,897 | 26,826 | 26.7 K to 26.8 K (+0.58 %) |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Option Exercise | A | 87.42 | 39,480 | 3,451,342 | 39,480 | |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 12,200 | 0 | 26,671 | 14.5 K to 26.7 K (+84.31 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 91.96 | 1,989 | 182,908 | 14,471 | 16.5 K to 14.5 K (-12.08 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 92.50 | 4,301 | 397,843 | 16,460 | 20.8 K to 16.5 K (-20.72 %) |
Mar 08 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 93.32 | 2,303 | 214,916 | 20,761 | 23.1 K to 20.8 K (-9.99 %) |
Mar 07 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 93.95 | 2,283 | 214,488 | 23,064 | 25.3 K to 23.1 K (-9.01 %) |
Jan 10 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 90.00 | 5,000 | 450,000 | 18,100 | 23.1 K to 18.1 K (-21.65 %) |
Nov 14 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 90.61 | 20,000 | 1,812,206 | 23,100 | 43.1 K to 23.1 K (-46.40 %) |
Nov 14 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 68.44 | 156 | 10,677 | 43,100 | 42.9 K to 43.1 K (+0.36 %) |
Sep 02 2016 | RLYP | Relypsa Inc | SPIEGELMAN DANIEL K | Director | Option Exercise | D | 17.00 | 4,500 | 76,500 | 0 | |
Sep 02 2016 | RLYP | Relypsa Inc | SPIEGELMAN DANIEL K | Director | Option Exercise | D | 35.79 | 4,500 | 161,055 | 0 | |
Sep 02 2016 | RLYP | Relypsa Inc | SPIEGELMAN DANIEL K | Director | Option Exercise | D | 23.96 | 12,000 | 287,520 | 0 | |
Sep 02 2016 | RLYP | Relypsa Inc | SPIEGELMAN DANIEL K | Director | Sell | D | 32.00 | 2,250 | 72,000 | 0 | 2.3 K to 0 (-100.00 %) |
Sep 02 2016 | RLYP | Relypsa Inc | SPIEGELMAN DANIEL K | Director | Sell | U | 32.00 | 1,237 | 39,584 | 2,250 | 3.5 K to 2.3 K (-35.47 %) |
Aug 03 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 99.33 | 4,000 | 397,320 | 42,944 | 46.9 K to 42.9 K (-8.52 %) |
Jun 28 2016 | ONTY | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Option Exercise | A | 0.00 | 54,347 | 0 | 54,347 | |
Jun 23 2016 | RLYP | Relypsa Inc | SPIEGELMAN DANIEL K | Director | Option Exercise | A | 17.00 | 4,500 | 76,500 | 4,500 | |
Jun 23 2016 | RLYP | Relypsa Inc | SPIEGELMAN DANIEL K | Director | Grant | A | 0.00 | 2,250 | 0 | 3,487 | 1.2 K to 3.5 K (+181.89 %) |
Jun 08 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 89.14 | 1,649 | 146,992 | 46,944 | 48.6 K to 46.9 K (-3.39 %) |
Jun 08 2016 | RLYP | Relypsa Inc | SPIEGELMAN DANIEL K | Director | Sell | S | 19.31 | 1,013 | 19,562 | 1,237 | 2.3 K to 1.2 K (-45.02 %) |
Jun 07 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 90.00 | 1,801 | 162,090 | 48,593 | 50.4 K to 48.6 K (-3.57 %) |
Jun 02 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Option Exercise | M | 39.06 | 16,896 | 659,958 | 2,604 | |
Jun 02 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 89.35 | 3,945 | 352,486 | 50,394 | 54.3 K to 50.4 K (-7.26 %) |
Jun 02 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 90.00 | 16,896 | 1,520,640 | 54,339 | 71.2 K to 54.3 K (-23.72 %) |
Jun 02 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Buy | M | 39.06 | 16,896 | 659,958 | 71,235 | 54.3 K to 71.2 K (+31.09 %) |
May 31 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 89.09 | 4,305 | 383,532 | 54,339 | 58.6 K to 54.3 K (-7.34 %) |
May 25 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 87.07 | 3,769 | 328,184 | 58,644 | 62.4 K to 58.6 K (-6.04 %) |
May 17 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 82.71 | 1,722 | 142,427 | 62,413 | 64.1 K to 62.4 K (-2.68 %) |
May 17 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 51.26 | 202 | 10,355 | 64,135 | 63.9 K to 64.1 K (+0.32 %) |
Mar 17 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Option Exercise | A | 83.43 | 37,290 | 3,111,105 | 37,290 | |
Mar 17 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 16,640 | 0 | 63,933 | 47.3 K to 63.9 K (+35.18 %) |
Mar 07 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 89.57 | 2,395 | 214,520 | 47,293 | 49.7 K to 47.3 K (-4.82 %) |
Mar 02 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 86.12 | 4,623 | 398,120 | 49,688 | 54.3 K to 49.7 K (-8.51 %) |
Mar 02 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 81.87 | 46,766 | 3,828,732 | 54,311 | 101.1 K to 54.3 K (-46.27 %) |
Feb 26 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 5,883 | 0 | 101,077 | 95.2 K to 101.1 K (+6.18 %) |
Feb 26 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 49,600 | 0 | 95,194 | 45.6 K to 95.2 K (+108.79 %) |
Feb 26 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 17,150 | 0 | 45,594 | 28.4 K to 45.6 K (+60.29 %) |
Nov 18 2015 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Option Exercise | M | 39.06 | 20,000 | 781,200 | 19,500 | |
Nov 18 2015 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 104.30 | 20,000 | 2,085,918 | 28,229 | 48.2 K to 28.2 K (-41.47 %) |
Nov 18 2015 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Buy | M | 39.06 | 20,000 | 781,200 | 48,229 | 28.2 K to 48.2 K (+70.85 %) |
Sep 28 2015 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Option Exercise | A | 0.00 | 14,245 | 0 | 14,245 | |
Jun 16 2015 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Option Exercise | M | 0.00 | 16,042 | 0 | 0 | |
Jun 16 2015 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Option Exercise | A | 0.00 | 12,886 | 0 | 12,886 | |
Jun 16 2015 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Payment of Exercise | F | 3.88 | 4,011 | 15,563 | 52,675 | 56.7 K to 52.7 K (-7.08 %) |
Jun 16 2015 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Buy | M | 0.00 | 16,042 | 0 | 56,686 | 40.6 K to 56.7 K (+39.47 %) |
Jun 08 2015 | RLYP | Relypsa Inc | SPIEGELMAN DANIEL K | Director | Option Exercise | A | 35.79 | 4,500 | 161,055 | 4,500 | |
Jun 08 2015 | RLYP | Relypsa Inc | SPIEGELMAN DANIEL K | Director | Grant | A | 0.00 | 2,250 | 0 | 2,250 | 0 to 2.3 K |
Jun 08 2015 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 122.30 | 1,649 | 201,669 | 28,229 | 29.9 K to 28.2 K (-5.52 %) |
Jun 08 2015 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 120.46 | 1,801 | 216,948 | 29,878 | 31.7 K to 29.9 K (-5.69 %) |
Jun 03 2015 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 124.16 | 3,945 | 489,811 | 31,679 | 35.6 K to 31.7 K (-11.07 %) |
Jun 03 2015 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 126.15 | 1,578 | 199,065 | 35,624 | 37.2 K to 35.6 K (-4.24 %) |
Jun 03 2015 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 125.57 | 4,305 | 540,579 | 37,202 | 41.5 K to 37.2 K (-10.37 %) |
May 28 2015 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 130.00 | 34,078 | 4,430,140 | 41,507 | 75.6 K to 41.5 K (-45.09 %) |
May 19 2015 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Buy | S | 124.77 | 2,059 | 256,905 | 75,585 | 73.5 K to 75.6 K (+2.80 %) |
May 19 2015 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 122.78 | 1,722 | 211,427 | 77,644 | 79.4 K to 77.6 K (-2.17 %) |
May 19 2015 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 51.26 | 88 | 4,511 | 79,366 | 79.3 K to 79.4 K (+0.11 %) |
Apr 01 2015 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Buy | P | 1.59 | 10,000 | 15,856 | 40,644 | 30.6 K to 40.6 K (+32.63 %) |
Apr 01 2015 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Buy | P | 1.63 | 10,000 | 16,271 | 30,644 | 20.6 K to 30.6 K (+48.44 %) |
Mar 05 2015 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Option Exercise | A | 108.36 | 23,900 | 2,589,804 | 23,900 | |
Mar 05 2015 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 10,500 | 0 | 79,278 | 68.8 K to 79.3 K (+15.27 %) |
Mar 04 2015 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Option Exercise | M | 39.06 | 15,500 | 605,430 | 39,500 | |
Mar 04 2015 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 107.00 | 15,500 | 1,658,500 | 68,676 | 84.2 K to 68.7 K (-18.41 %) |
Mar 04 2015 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Buy | M | 39.06 | 15,500 | 605,430 | 84,176 | 68.7 K to 84.2 K (+22.57 %) |
Apr 08 2004 | CVTX | CV THERAPEUTICS IN ... | SPIEGELMAN DANIEL K | Senior Vice Preside ... | Grant | A | 14.67 | 682 | 10,005 | 1,524 | 842 to 1.5 K (+81.00 %) |
Page: 1